RxDoctor Payments Data

Ann Marie Gordon, MD

Internal Medicine · Washington, DCNPI 1053480269

Payments from drug & device makers

$3,941in general payments, 2019–2025

Across 161 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$709
  • Novo Nordisk$663
  • Amgen$634
  • Boehringer Ingelheim$531
  • Lilly USA, LLC$530
  • Lundbeck LLC$195
  • plus $678 from 8 others

What the payments were for

  • Food & beverage$3,921100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,941 in reported general payments places this provider in the 85th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$56,602
Medicare patients
95
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$63,860
JardianceEmpagliflozin19$26,141
RybelsusSemaglutide13$15,637
Nebivolol Hcl20$1,430
Tramadol Hcl22$816
Tizanidine Hcl16$765
Metoprolol Succinate52$719
Rosuvastatin Calcium54$697
Gabapentin25$671
Levothyroxine Sodium60$589
Valsartan14$584
Pravastatin Sodium31$488
Atorvastatin Calcium66$485
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide34$454
Amlodipine Besylate111$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$663$79,49758 claims
Boehringer IngelheimJardiance$531$26,14119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →